Jiao Zhang

Jiao Zhang

Auto-generated profile, based on publicly available information

Jiao Zhang

Texas Children’s Cancer and Hematology Center, Texas Children’s Hospital, Houston, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
NANamal Abeysundara
Namal Abeysundara
ARAlexandra Rasnitsyn
Alexandra Rasnitsyn
VFVernon Fong
Vernon Fong
ABAlexander Bahcheli
Alexander Bahcheli
RORandy Van Ommeren
Randy Van Ommeren
MTMichael D. Taylor
Michael D. Taylor
Leptomeningeal metastases are the major source of morbidity and mortality for patients with medulloblastoma. The biology of the leptomeningeal metastases and the local tumour microenvironment are poorly characterized. Here we show that metastasis-associated meningeal fibroblasts (MB-MAFs) are transcriptionally distinct and signal extensively to tumour cells and the tumour microenvironment. Metastatic cells secrete platelet-derived growth factor (PDGF) ligands into the local microenvironment to chemotactically recruit meningeal fibroblasts. Meningeal fibroblasts are reprogrammed to become MB-MAFs, expressing distinct transcriptomes and secretomes, including bone morphogenetic proteins. Active bone morphogenetic protein signalling and co-implantation of tumour cells with MB-MAFs enhances the colonization of the leptomeninges by medulloblastoma cells and promotes the growth of established metastases. Furthermore, treatment of patient-derived xenograft mice with a PDGF-receptor-α neutralizing antibody enhances overall survival in vivo. Collectively, our results define a targetable intercellular communication cascade in the metastatic niche to treat leptomeningeal disease.

27 April 2018 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
JZJiao Zhang
Jiao Zhang
KWONG Tak Wu SamKWONG Tak Wu Sam
KWONG Tak Wu Sam
GLGuangming Liu
Guangming Liu
QLQiuzhen Lin
Qiuzhen Lin
Ka-Chun WongKa-Chun Wong
Ka-Chun Wong
Pathway analysis is a cornerstone of system biology. In particular, pathway similarity search plays a key role in establishing structural, functional, and evolutionary relationships between different biological entities. Given a query pathway as well as a database, a pathway similarity search aims to identify novel pathways that are homologous to the query pathway. Unfortunately, the pathway similarity search is computationally inefficient due to the NP-complete graph isomorphism problem. In this current study, we introduce a novel algorithmic framework for pathway similarity search, named PathEmb (Pathway Embedding), which is analogous to the Skip-gram model where each pathway is represented as a "document". PathEmb exploits a second order random walk strategy to explore diverse pathway patterns. All signaling paths traversed from random walks are regarded as "sentences", which are constituted as a "document" afterwards. Then, the "document" pattern for the individual pathway is mapped into a low-dimensional feature space for downstream tasks. Furthermore, PathEmb is a topology-free pathway similarity search algorithm, which is feasible to handle any pathway with arbitrary structure. We have extensively evaluated PathEmb and other cutting-edge methods on three pathway datasets. The experimental results demonstrate that PathEmb outperforms the existing methods in terms of computational efficiency and search accuracy. The source codes of PathEmb are freely available online https://github.com/zhangjiaobxy/PathEmb.

25 July 2025 in Cancer Research
Verified
Journal Article
Open access
CRCory M. Richman
Cory M. Richman
ARAlexandra Rasnitsyn
Alexandra Rasnitsyn
BHBorja L. Holgado
Borja L. Holgado
MVMaria Vladoiu
Maria Vladoiu
NANamal Abeysundara
Namal Abeysundara
PAPasqualino De Antonellis
Pasqualino De Antonellis
Group 3 (G3) medulloblastoma constitutes the most aggressive molecular subgroup, and nearly all patients present with metastases upon recurrence. Treatment for newly diagnosed medulloblastoma relies on a combination of maximal safe surgical resection, followed by chemotherapy and ionizing radiation, and no therapies have been shown to confer a survival benefit at the time of recurrence. Given the limited therapeutic options available for patients with medulloblastoma, especially at recurrence, and the incomplete understanding of the molecular mechanisms underlying resistance to treatment, we sought to uncover actionable targets and biomarkers that could help refine patient selection and treatment of newly diagnosed medulloblastoma to reduce the risk of recurrence. In clinically relevant mouse models of G3 medulloblastoma, CT-guided fractionated radiotherapy extended overall survival and induced the clonal selection of radioresistant subpopulations of tumor cells that drove medulloblastoma recurrence. Comparison of recurrent tumors with treatment-naïve newly diagnosed tumors revealed a gene expression signature that was found to be a biomarker of radioresistance and poor prognosis. This prognostic gene signature was shown to be subgroup specific in a large patient cohort. Recurrent tumors had elevated expression of carbonic anhydrase 4, and genetic and pharmacologic modulation of carbonic anhydrase 4 could promote or reduce resistance to radiotherapy. These data suggest that the FDA-approved carbonic anhydrase inhibitor acetazolamide may be a useful radiosensitizer to improve the efficacy of the treatment of newly diagnosed G3 medulloblastoma that could reduce the risk of tumor recurrence and improve survival in pediatric patients. Significance: G3 medulloblastoma features a prognostic subgroup-specific gene expression signature and can be targeted with a carbonic anhydrase inhibitor to enhance radiosensitivity, reducing the risk of recurrence and improving survival.

25 March 2026 in Nature
Verified
Journal Article
Open access
PDF file
JZJiao Zhang
Jiao Zhang
WOWinnie Ong
Winnie Ong
ARAlexandra Rasnitsyn
Alexandra Rasnitsyn
RGRicardo Daniel Gonzalez
Ricardo Daniel Gonzalez
RGRodrigo Lopez Gutierrez
Rodrigo Lopez Gutierrez
MTMichael D. Taylor
Michael D. Taylor
Posterior fossa type A (PFA) ependymoma is an unusual infantile brain tumour with few known somatic mutations, thought to be driven by epigenetic mechanisms1. PFA ependymoma has a markedly higher incidence and worse prognosis in male children than in female children2. The mechanisms that underlie these sex differences are at present unknown. Here we show that the cellular hierarchy of PFA ependymoma is less differentiated in male individuals than it is in female individuals. In the normal developing mouse hindbrain, male gliogenic progenitors are less differentiated than matched female sibling controls. To further parse the effects of chromosomal versus gonadal contributions in the male hindbrain, we used the four-core genotype mouse model3, which showed that androgen signalling, rather than sex chromosomes, prolongs hindbrain differentiation in male mice. Androgen supplementation promotes the growth of PFA ependymoma, but not that of other brain tumours. Conversely, androgen blockade diminishes both the stem-like potential and the proliferation of PFA ependymoma. We conclude that androgen signalling in both the normal developing hindbrain and PFA ependymoma is sufficient to promote growth and delay differentiation. Anti-androgen therapies represent a potential clinical avenue to target this currently untreatable childhood cancer.

3 November 2017 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
JZJiao Zhang
Jiao Zhang
KWONG Tak Wu SamKWONG Tak Wu Sam
KWONG Tak Wu Sam
Ka-Chun WongKa-Chun Wong
Ka-Chun Wong
Pathway similarity search plays a vital role in the post-genomics era. Unfortunately, pathway similarity search involves the graph isomorphism problem which is NP-complete. Therefore, efficient search algorithms are desirable. In this work, we propose a novel global pathway similarity search approach named ToBio, which considers both topological and biological features for effective global pathway similarity search. Specifically, as motivated from nature, various topological and biological features including subgraph signature similarities, sequence similarities, and gene ontology similarities are considered in ToBio. Since different features carry different functional importance and dependences, we report three schemes of ToBio using different sets of features. In addition, to enhance the existing search algorithms for rigorous comparisons, post-processing pipelines are also proposed to investigate how different features can contribute to the search performance. ToBio and other state-of-the-art methods are benchmarked on the gold-standard pathway datasets from three species; the results demonstrate the competitive edges of ToBio over the state-of-the-arts ranging from the topological aspects to the biological aspects. Case studies have been conducted to reveal mechanistic insights into the unique search performance of ToBio.

10 March 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
YSYu Su
Yu Su
KDKaiwen Deng
Kaiwen Deng
XCXuan Chen
Xuan Chen
ZFZhaoyang Feng
Zhaoyang Feng
DWDongyang Wang
Dongyang Wang
YTYu Tian
Yu Tian
Background Medulloblastoma (MB), the most common malignant pediatric brain tumor, lacks prognostic tools integrating clinical, molecular, and treatment-related characteristics for individualized management. Methods We developed machine learning models using multicenter data from 729 Chinese patients (2001-2023), of whom 509 were assigned to the training set and 220 to the testing set, and further validated the models on 201 patients from international MB consortia. To accommodate patients and researchers with varying datatypes, four application scenarios were established, including clinical-molecular-radiotherapy (CMR), clinical-molecular (CM), clinical-radiotherapy (CR), and clinical-only (CO). Results We construct four model scenarios and assess their predictive performance in the testing set: an XGBoost-based CMR model (incorporating 11 features, including molecular subgroup, radiotherapy dose, and key gene expression) with a C-index of 0.612; an XGBoost-based CM (C-index = 0.609); a GBM-based CR (C-index = 0.637); and a GBM-based CO (C-index = 0.635). External validation demonstrates robust performance, with radiotherapy and molecular data contributing significantly to enhanced efficacy. In addition, interactive web-based Shiny applications have been launched to facilitate dynamic risk assessment and treatment optimization. Conclusions By integrating multidimensional data, our framework enables the tailored prognostication and clinical decision to meet the multidimensional requirements of research and medicine.